Multiple regions of ligand discrimination revealed by analysis of chimeric parathyroid hormone 2 (PTH2) and PTH/PTH-related peptide (PTHrP) receptors

Molecular Endocrinology

Volumn 12, Issue 2, 1998, Pages 193-206

  Clark, J A ^a   Bonner, T I ^a   Kim, A S ^a   Usdin, T B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CHIMERA; HUMAN; LIGAND BINDING; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY;

EID: 0032230141     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.12.2.0063     Document Type: Article

References (45)

1. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide
2. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor
3. Serpentine receptors for parathyroid hormone, calcitonin and extracellular calcium ions
4. Role of the extracellular regions of the parathyroid-hormone (PTH) PTH-related peptide receptor in hormone-binding
5. Homolog-scanning mutagenesis of the parathyroid hormone (PTH) receptor reveals PTH(1-34) binding determinants in the third extracellular loop
6. Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP
7. Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane
8. Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide hisidine isoleucineamide
9. Aspartate 196 in the first extracellular loop pf the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production
10. Transmembrane residues of the parathyroid hormone (PTH)/PTH-related peptide receptor that specifically affect binding and signalling by agonist ligands
11. Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP)1 receptor identifies seven mutants that are defective in VIP binding
12. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor
13. Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor
14. Chimeric human calcitonin and glucagon receptors reveal two dissociable calcitonin interaction sites
15. Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination
16. Lysine 173 residue within the first exoloop of rat secretin receptor is involved in carboxylate moiety recognition of Asp 3 in secretin
17. Mutations of neighboring polar residues on the second transmembrane helix disrupt signaling by the parathyroid hormone receptor
18. A putative selectivity filter in the G-protein-coupled receptors for parathyroid hormone and secretin
19. The extracellular aminoterminal region of the parathyroid hormone (PTH)/PTH-related peptide receptor determines the binding affinity for carboxyl-terminal fragments of PTH-(1-34)
20. Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin. Evidence for a common pattern of ligand-receptor interaction
21. Direct mapping of an agonist-binding domain within the parathyroid hormone/parathyroid hormone-related protein receptor by photoaffinity crosslinking
22. Parathyroid hormone: Physiology, chemistry, biosynthesis, secretion, metabolism and mode of action
23. The human PTH2 receptor: Binding and signal transduction properties of the stably expressed recombinant receptor
24. Parathyroid hormone-related protein
25. The rat, mouse and human genes encoding the receptor for parathyroid hormone and parathyroid hormone-related peptide are highly homologous
26. 2]PTH-(1-34) binding and signaling in the transmembrane region of the parathyroid hormone receptor
27. The C-terminus ends of secretin and VIP interact with the N- terminal domains of their receptors
28. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptidel, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptidel receptors: Evidence for multiple receptor states
29. A constitutively active mutant PTH- PTHrP receptor in Jansen-Type metaphyseal chondrodysplasia
30. The probable arrangement of the helices in G protein-coupled receptors
31. Allele-specific activation of genetically engineered receptors
32. Interaction of substance P with the second and seventh transmembrane domains of the neurokinin-1 receptor
33. 383 in the second transmembrane domain of the lutropin receptor is important for high affinity hormone binding and cAMP production
34. Identification of residues required for ligand binding to the β-adrenergic receptor
35. Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding
36. Mutation of peptide binding site in transmembrane region of a G protein-coupled receptor accounts for endothelin receptor subtype selectivity
37. Critical role of a conserved intramembrane tyrosine residue in angiotensin II receptor activation
38. A rapid and simple method for introducing specific mutations into any position of DNA leaving all other positions unaltered
39. High efficiency polyoma DNA transfection of chloroquine treated cells
40. Introduction of DNA into mammalian cells
41. Vaccinia-T7 RNA polymerase expression system: Evaluation for the expression cloning of plasma membrane transporters
42. Calcium dependence of betaadrenoreceptor mediated cyclic AMP accumulation in human lymphocytes
43. Radioimmunoassay of cyclic AMP and cyclic GMP
44. Microdialysis of extracellular endogenous opioid peptides from rat brain in vivo
45. LIGAND: A versatile computerized approach for characterization of ligand-binding systems